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Patients with mutation L394R in g-glutamyl carboxyl-
ase have a severe bleeding disorder because of de-
creased biological activities of all vitamin K-dependent
coagulation proteins. Vitamin K administration par-
tially corrects this deficiency. To characterize L394R,
we purified recombinant mutant L394R and wild-type
carboxylase expressed in baculovirus-infected insect
cells. By kinetic studies, we analyzed the catalytic activ-
ity of mutant L394R and its binding to factor IX’s
propeptide and vitamin KH2. Mutant L394R differs from
its wild-type counterpart as follows: 1) 110-fold higher Ki
for Boc-mEEV, an active site-specific, competitive inhib-
itor of FLEEL; 2) 30-fold lower Vmax/Km toward the sub-
strate FLEEL in the presence of the propeptide; 3) se-
verely reduced activity toward FLEEL carboxylation in
the absence of the propeptide; 4) 7-fold decreased affin-
ity for the propeptide; 5) 9-fold higher Km for FIXproGla,
a substrate containing the propeptide and the Gla do-
main of human factor IX; and 6) 5-fold higher Km for
vitamin KH2. The primary defect in mutant L394R ap-
pears to be in its glutamate-binding site. To a lesser
degree, the propeptide and KH2 binding properties are
altered in the L394R mutant. Compared with its wild-
type counterpart, the L394R mutant shows an aug-
mented activation of FLEEL carboxylation by the
propeptide.
Vitamin K-dependent carboxylase, also known as g-glutamyl
carboxylase, an integral membrane protein residing in the
rough endoplasmic reticulum, catalyzes the posttranslational
modification of specific glutamic acid residues to g-carboxyglu-
tamic acid (Gla)1 in vitamin K-dependent proteins (1). Gla-
containing proteins are involved in blood coagulation (2), bone
metabolism (3), and regulation of cell proliferation (4). The Gla
domains of blood coagulation and anticoagulation proteins me-
diate calcium-dependent interactions between the protein and
phospholipid membranes (5), a process necessary for the bio-
logical activity of these proteins. In addition to the glutamate
substrate, g-glutamyl carboxylation requires carbon dioxide,
oxygen, and the essential cofactor vitamin K hydroquinone
(KH2), which is the reduced form of vitamin K (6). The forma-
tion of Gla from glutamate is coupled with the conversion of
vitamin KH2 to vitamin K 2,3-epoxide. Both of these activities
occur in the vitamin K-dependent carboxylase (7, 8). The war-
farin-sensitive microsomal enzyme vitamin K epoxide reduc-
tase recycles the epoxide back to vitamin KH2 (9), thus com-
pleting the vitamin K cycle.
There have been only a few cases of combined deficiencies of
vitamin K-dependent coagulation factors reported (10–18). Pa-
tients with this disorder suffer from a bleeding diathesis due to
deficiencies of prothrombin and factors VII, IX, and X. In ad-
dition, the anticoagulation activities of proteins C and S are
decreased. Brenner et al. (16) reported that patients’ coagula-
tion activities were severely reduced, while their antigen levels
were only moderately decreased. Abnormality of the vitamin K
epoxide reductase was ruled out because the patients had un-
detectable serum levels of vitamin K epoxide, and the hepatic
vitamin K intake and skeletal development were both normal
(18). Because the coagulation activities of these patients were
partially corrected by administration of vitamin K and because
prothrombin with impaired Gla-mediated calcium binding was
identified, a defect in the vitamin K-dependent carboxylase was
suspected (16). Genetic analysis of the proband (16) and her
three affected siblings (18) revealed a mutation in the g-glu-
tamyl carboxylase gene (18). All were homozygous for a T3 G
point mutation in exon 9 of the carboxylase gene. This muta-
tion results in the substitution of arginine for leucine at residue
394, a conserved residue found in the g-glutamyl carboxylase of
human (19), bovine (20), rat (21), Drosophila (22), mouse,
whale, and toadfish (23). Furthermore, leucine 394 resides in a
conserved region with 90% sequence identity spanning resi-
dues 374–405 (22, 23), which implies a functional or structural
importance for this region. In this report, we compare the
functional properties of the L394R mutant g-glutamyl carbox-
ylase to those of its wild-type counterpart. Our results indicate
that the major defect of mutation L394R is at or near its
glutamate-binding site. Furthermore, an augmented allosteric
effect between the propeptide- and glutamate-binding sites is
observed in the L394R mutant.
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EXPERIMENTAL PROCEDURES
Materials—FLEEL was purchased from Bachem (Philadelphia, PA).
L-a-Phosphatidylcholine (type V-E), CHAPS, and pepstatin were from
Sigma. Vitamin K1 was from Abbott. FIXproGla, a 59-residue recombi-
nant peptide containing the propeptide and first 41 residues of the Gla
domain of human factor IX, was prepared and purified as described
(24). The peptide ProFIX19, which contains the sequence AVFLD-
HENANKILNRPKRY, was synthesized by Dr. Frank Church (Univer-
sity of North Carolina, Chapel Hill). The peptide Boc-mEEV was syn-
thesized as described (25). NaH14CO3 (specific activity, 56 mCi/mmol)
was from ICN Pharmaceuticals (Costa Mesa, CA). Leupeptin, aprotinin,
and phenylmethylsulfonyl fluoride were from Roche Molecular Bio-
chemicals. The pSK2 vector was from Stratagene (La Jolla, CA). The
pVL1392 vector was from Pharmingen (San Diego, CA). The BacVector
3000 baculoviral DNA was from Novagen (Madison, WI). Sf9 (Spodopt-
era frugiperda) insect cells were obtained from the Lineberger Cancer
Center at the University of North Carolina (Chapel Hill, NC). High Five
(Trichoplusia ni) insect cells were provided by Dr. Thomas Kost of
Glaxo Wellcome. HPC4 antibody affinity resin was provided by Dr.
Charles Esmon (Oklahoma Medical Research Foundation, Oklahoma
City, OK). The anti-FLAG M2 monoclonal antibody and Met-FLAG-
bacterial alkaline phosphatase were from Sigma. Peroxidase-conju-
gated goat anti-mouse immunoglobulin was from Jackson ImmunoRe-
search (West Grove, PA). ECL Western blotting detection reagents were
from Amersham Pharmacia Biotech.
Expression and Purification of Recombinant Wild-type and L394R
Mutant Carboxylase—The cDNA for human g-glutamyl carboxylase
(19), cloned into the pSK2 vector, was modified by site-specific mu-
tagenesis (26) to make the L394R mutant. Both wild-type and mutant
constructs contain the FLAG epitope (DYKDDDDK) attached to their
amino termini and the HPC4 tag containing the sequence EDQVD-
PRLIDGK (27) at their carboxyl termini. The engineered DNA con-
structs, coding for wild-type and mutant carboxylase, were subcloned
into the pVL1392 vector, and the proteins were expressed in baculovi-
rus-infected High Five cells as described (28).
Isolation of microsomes from High Five cells was performed as de-
scribed (29) with minor modifications. Cells (8–10 3 108) harvested
from 1 liter of a culture were washed with 300 ml of cold buffer
containing 25 mM Tris, pH 7.4, 150 mM NaCl, and 15% glycerol. The
washed cell pellet was resuspended in 120 ml of cold buffer containing
protease inhibitor mixture, which contains 2 mM dithiothreitol, 0.5
mg/ml leupeptin, 1 mg/ml pepstatin, 2 mg/ml aprotinin, and 0.1 mg/ml
phenylmethylsulfonyl fluoride, and disrupted by sonication (with 80
pulses, 1.5 s each, using a Heat Systems XL2020 sonicator at a power
output of 6). The homogenate was centrifuged at 4300 3 gavg at 4 °C for
15 min. The supernatant was recovered and centrifuged at 150,000 3
gavg for 1 h. at 4 °C. Solubilization of the microsomal pellet and the
subsequent purification of carboxylase using the HPC4 antibody affin-
ity resin were performed as described (28).
SDS-Polyacrylamide Gel Electrophoresis and Western Blot Analy-
sis—Purified carboxylase was analyzed by silver-stained SDS-poly-
acrylamide gel electrophoresis (10% polyacrylamide gels; Bio-Rad) and
by Western blot analysis. For Western blot analysis, the proteins trans-
ferred to a polyvinylidene difluoride membrane were probed with the
anti-FLAG M2 monoclonal antibody (1.4 mg/ml) and then with the
peroxidase-conjugated secondary antibody (0.07 mg/ml). The FLAG tag-
containing proteins were detected by chemiluminescence following in-
cubation of the membranes with ECL reagents (Amersham Pharmacia
Biotech) and autoradiography on Hyperfilm (Amersham Pharmacia
Biotech). The wild-type and mutant carboxylases were quantitated by
dot blot analysis on polyvinylidene difluoride membranes using known
amounts of Met FLAG-bacterial alkaline phosphatase as standards.
The FLAG tag-containing carboxylase and the standard were detected
using anti-FLAG M2 antibody. Quantification was made based on the
analysis of autoradiographs using an ImageQuant densitometer (Mo-
lecular Dynamics, Inc., Sunnyvale, CA).
Carboxylase Activity Assays—The in vitro carboxylase activity assays
were performed as described (24) with minor modifications. Reactions
were performed at 20 °C in 25 mM MOPS, pH 7.4, 500 mM NaCl, 0.16%
phosphatidylcholine, 0.16% CHAPS, 222 mM vitamin KH2, 1.4 mM
NaH14CO3 (10 mCi), and various concentrations of FLEEL or FIXpro-
Gla. In FLEEL carboxylation assays, ProFIX19 at 5 mM was also
included.
Vitamin K Epoxidase Activity Assay—Carboxylations of FLEEL in
the presence of 5 mM ProFIX19 were performed as described above,
except that unlabeled NaHCO3 was used. FLEEL concentrations of 1
and 12 mM were used in the wild-type and mutant reactions, respec-
tively. Vitamin K epoxide formation was quantitated as described (30).
Kinetic Studies—For the kinetic studies of FLEEL carboxylation, 5
mM ProFIX19 was included. All components used in the assay were
premixed except vitamin KH2 and NaH
14CO3, which were added to
start the reaction. The assays were carried out for 30 min for carbox-
ylation of FLEEL and 1 h for carboxylation of FIXproGla. In vitamin
KH2 kinetic studies, the concentration of dithiothreitol was kept con-
stant (6 mM) in all reactions, which were performed for 30 min.
Inhibition of FLEEL Carboxylation by Boc-mEEV—The tripeptide
Boc-mEEV, containing a modified amino acid (2S,4S)-4-methylglutamic
acid, is a strong competitive inhibitor of carboxylase toward FLEEL
carboxylation (25, 31). Boc-mEEV was used to compete with 0.8 mM
FLEEL for the wild-type carboxylase and with 10 mM FLEEL for the
mutant L394R.
Inhibition of FIXproGla Carboxylation by Free Propeptide—We ex-
amined the effect of the free propeptide on the carboxylation of FIXpro-
Gla, which contains a propeptide covalently linked to the Gla domain of
factor IX. ProFIX19 was used to compete with 0.5 mM FIXproGla for the
wild-type carboxylase and with 4.0 mM FIXproGla for the mutant
L394R.
Stimulation of FLEEL Carboxylation by ProFIX19—The reactions
were carried out as described above, using 1 mM of FLEEL for the
wild-type carboxylase and 12 mM of FLEEL for the mutant L394R and
varying the ProFIX19 concentration up to 2.4 mM.
RESULTS
Expression of the Recombinant Wild-type and L394R Mutant
Carboxylase—The recombinant wild-type and L394R mutant
carboxylase, expressed in baculovirus-infected High Five cells,
contain FLAG tags at their amino termini and HPC4 tags at
their carboxyl termini. These epitopes, which lie outside the
coding region of the carboxylase, facilitate the identification,
purification, and quantification of the recombinant proteins.
The recombinant carboxylase was affinity-purified using an
HPC4 antibody column. The purification method employed pro-
vides carboxylase of high purity (Fig. 1). The estimated molec-
ular mass of the proteins is around 95 kDa, similar to that
reported for the purified carboxylase (32). Western blot analy-
sis revealed a single antibody-reactive band at 95 kDa in both
the wild-type and mutant carboxylase preparations (Fig. 1) and
indicates the absence of proteolysis in either preparation.
FIG. 1. SDS-polyacrylamide gel electrophoresis and Western
blot analysis of the carboxylases. Purified proteins were fraction-
ated by 10% reducing SDS-polyacrylamide gel electrophoresis and de-
tected with silver staining or transferred onto a polyvinylidene difluo-
ride membrane. For Western blot, the proteins on membrane were
probed with the anti-FLAG M2 monoclonal antibody and detected using
ECL reagents. A, silver-stained gel. Lane 1, wild-type carboxylase; lane
2, mutant L394R. B, Western blot. Lane 1, wild-type carboxylase; lane
2, mutant L394R. Molecular mass standards are shown on the sides.
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Effect of ProFIX19 on FLEEL Carboxylation—The free
propeptide of the vitamin K-dependent coagulation proteins
has been shown to enhance the rate of carboxylation of small
glutamate-containing peptide substrates that lack a covalently
linked propeptide sequence (33, 34). We therefore used Pro-
FIX19, the propeptide sequence of factor IX, to compare its
effect on the carboxylation of FLEEL by the wild-type and
mutant carboxylases. In the absence of the free propeptide, the
wild-type carboxylase exhibits significant activity toward
FLEEL carboxylation. As shown in Fig. 2, the rate of FLEEL
carboxylation by the wild-type carboxylase increased 5–6-fold
when saturating amounts of ProFIX19 were added. In contrast,
mutant L394R showed almost undetectable activity toward
FLEEL in the absence of the free propeptide. However, this
deficiency can be ameliorated by adding ProFIX19. Compared
with its wild-type counterpart, a higher concentration of Pro-
FIX19 was required to achieve maximal stimulation of FLEEL
carboxylation by mutant L394R. The concentrations of pro-
FIX19 determined for half-maximal stimulation were 26 6 3
and 409 6 27 nM for the wild type and mutant L394R, respec-
tively. These results demonstrate that mutant L394R has a
decreased affinity for ProFIX19 when compared with the wild-
type enzyme.
FLEEL Carboxylation—Kinetic constants for FLEEL car-
boxylation were determined in the presence of saturating con-
centrations of ProFIX19 (Table I). As shown in Fig. 3, substrate
inhibition was apparent at high concentrations of FLEEL. This
phenomenon was previously seen in the purified bovine carbox-
ylase (8). Inhibition occurred when FLEEL concentrations were
greater than 9 mM for the wild type and 18 mM for the mutant
L394R. All kinetic constants were derived from the Michaelis-
Menten equation using data below the inhibitory concentra-
tions of FLEEL. Comparison of Vmax for FLEEL carboxylation
showed that the reaction rate of mutant L394R was 2.5-fold
slower than that of the wild-type (Fig. 3, Table I). The Km of
FLEEL for mutant L394R is 6.49 6 0.72 mM, which is 12-fold
higher than that of the wild-type (0.54 6 0.10 mM). It was
impossible to determine the Km of FLEEL for mutant L394R in
the absence of the propeptide, even when FLEEL concentra-
tions were increased up to 60 mM, because its activity is almost
undetectable under such conditions.
Active Site Inhibition Studies—To examine the glutamate
binding properties of mutant L394R, we used the active site-
specific, competitive inhibitor Boc-mEEV (25). As shown in Fig.
4, by fitting the data into the competitive inhibition equation,
the Ki of Boc-mEEV is 0.013 6 0.002 mM for wild-type carbox-
ylase compared with 1.44 6 0.16 mM for mutant L394R. These
results revealed a 110-fold difference in the apparent affinities
of wild type and L394R for Boc-mEEV.
Vitamin K Epoxide Formation—The rate of vitamin K ep-
oxide formation was 20.3 6 0.5 pmol of KO/min/pmol of mutant
L394R versus 36.6 6 3.9 pmol of KO/min/pmol of wild-type
carboxylase. This 1.8-fold reduction in epoxide formation ob-
served in mutant L394R compared with the wild type carbox-
ylase parallels the 2.5-fold difference observed in FLEEL car-
boxylation, suggesting that the L394R mutant’s carboxylase
and epoxidase activities remain coupled (8, 36).
Carboxylation of FIXproGla—FIXproGla, a peptide sub-
strate containing the propeptide covalently linked to the Gla
domain of human factor IX, mimics the physiological substrate
of vitamin K-dependent carboxylase (24, 35). Carboxylation of
FIXproGla by the wild-type and mutant L394R carboxylase
follows Michaelis-Menten kinetics. The Km of FIXproGla by
wild-type carboxylase was 0.23 6 0.03 mM, which is 3 orders of
magnitude lower than that for FLEEL and is in agreement
with previous reports (24, 37, 38). As shown in Fig. 5 and Table
I, the Km of FIXproGla is 2.08 6 0.23 mM for mutant L394R,
which is 9-fold higher than that of the wild-type carboxylase.
Interestingly, the Vmax of FIXproGla carboxylation by mutant
L394R was 2-fold higher than that by the wild-type
carboxylase.
Inhibition of FIXproGla Carboxylation by Free Propeptide—
The propeptide of factor IX has been shown to be a competitive
inhibitor of FIXproGla carboxylation (28, 35). To obtain a better
estimate of their relative affinities for the propeptide, we com-
pared the Ki values of the wild type and L394R mutant for the
inhibition of FIXproGla carboxylation by ProFIX19. The Ki
values determined for wild-type and mutant L394R carboxy-
lases were 63 6 13 and 459 6 28 nM, respectively (Fig. 6). This
observed decrease in the relative affinity toward ProFIX19 by
the mutant L394R agrees with our results obtained from stud-
ies of ProFIX19 activation of FLEEL carboxylation.
Effect of Vitamin K Hydroquinone on Carboxylation—Since
mutant L394R has a higher Km for FIXproGla than that of the
wild-type carboxylase (Table I), 10.0 and 1.2 mM FIXproGla
were used for mutant L394R and for the wild-type carboxylase,
respectively, in this study; the experiment was designed so that
the substrates were 5-fold greater than the Km for each en-
zyme. As shown in Fig. 7 and Table I, the Km of vitamin KH2
was 7.0 6 1.2 mM for the wild-type carboxylase and 32.8 6 5.4
mM for mutant L394R. The Vmax of vitamin KH2 for the carbox-
ylation of FIXproGla was 1.9-fold higher for the mutant L394R
than that for the wild-type carboxylase.
DISCUSSION
The purposes of this study were to identify the mechanistic
defect of mutant L394R g-glutamyl carboxylase (16, 18) and to
relate the functional properties of the mutant enzyme to the
clinical symptoms of patients bearing this mutation. Our data
suggest that the major defect of L394R is its ability to bind
glutamate-containing substrates. The most convincing evi-
dence for this conclusion is that the Ki of the competitive
inhibitor of FLEEL carboxylation, Boc-mEEV, is 110-fold
higher for L394R than that for the wild-type carboxylase (Fig.
4). Furthermore, our results demonstrate that, in the absence
of the propeptide, the catalytic activity of L394R toward
FLEEL carboxylation is less than 1% of the wild type’s activity.
It is striking that saturating concentrations of the factor IX
propeptide increased carboxylation of FLEEL by L394R 200–
FIG. 2. Stimulation of FLEEL carboxylation by ProFIX19. Car-
boxylation of FLEEL was measured by 14CO2 incorporation, and reac-
tions were performed at 1 and 12 mM FLEEL for the wild-type carbox-
ylase (filled squares) and mutant L394R (filled circles), respectively.
ProFIX19, at concentrations between 0–2.4 mM, was used in these
experiments. The half-maximal stimulation concentration of ProFIX19
is 26 6 3 and 409 6 27 nM for the wild type and mutant L394R,
respectively.
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300 times (compared with 5–6 times for wild-type carboxylase).
Nevertheless, primarily because of its 12-fold increased Km, the
catalytic efficiency (Vmax/Km) of L394R toward the small sub-
strate FLEEL was, in the presence of propeptide, still 30-fold
lower than wild-type carboxylase (Table I). While the Km can
only be used as an approximation of substrate affinity, the
increased Km for FLEEL is consistent with our results with the
competitive inhibitor Boc-mEEV. Thus, the mutation of leucine
TABLE I
Comparison of the kinetic parameters of wild-type and L394R carboxylases
Values were determined as described under “Experimental Procedures.”
Substrate Enzyme Km Vmax Vmax/Km
mM pmol 14CO2/h/pmol enzyme pmol
14CO2/h/pmol
enzyme/mM
FLEELa Wild type 541 6 97 446 6 73 0.87 6 0.19
L394R 6490 6 724 178 6 15 0.028 6 0.005
FIXproGla Wild type 0.23 6 0.03 47 6 2 205 6 18
L394R 2.08 6 0.23 98 6 20 48 6 9
Vitamin KH2
b Wild type 7.0 6 1.2 42 6 3 6.1 6 0.8
L394R 32.8 6 5.4 78 6 8 2.3 6 0.5
a Determined at 5 mM ProFIX19.
b Determined at 1.2 and 10.0 mM FIXproGla in wild-type and mutant enzyme reactions, respectively.
FIG. 3. Carboxylation of FLEEL. Carboxylation of FLEEL, meas-
ured by 14CO2 incorporation, was performed in the presence of 5 mM
ProFIX19, a concentration that maximally stimulates both wild type
and mutant L394R. Concentrations of FLEEL between 0 and 12 mM
were used for the wild-type carboxylase (filled squares) and between 0
and 24 mM for mutant L394R (filled circles). The Km is 0.54 6 0.10 mM
for the wild-type carboxylase and 6.49 6 0.72 mM for mutant L394R.
FIG. 4. Inhibition of FLEEL carboxylation by the active site
specific inhibitor Boc-mEEV. The relative rates (Vi/Vo) of FLEEL
carboxylation for the wild-type carboxylase (filled squares) and mutant
L394R (filled circles) are plotted versus the concentration of Boc-mEEV.
Vo is
14CO2 incorporation in the absence of Boc-mEEV, and Vi is
14CO2
incorporation at a given concentration of Boc-mEEV. The reactions
were performed at 5 mM ProFIX19 with 0.8 mM FLEEL (1.5-fold Km) for
the wild-type carboxylase or with 10.0 mM FLEEL (1.5-fold Km) for
mutant L394R. The Ki determined is 0.013 6 0.002 and 1.44 6 0.16 mM
for the wild type and mutant L394R, respectively.
FIG. 5. Carboxylation of FIXproGla. Carboxylation of FIXproGla
is measured by 14CO2 incorporation. FIXproGla concentrations between
0 and 4.8 mM were used for wild-type carboxylase (filled squares) and
between 0 and 12.0 mM for mutant L394R (filled circles). The Km is
0.23 6 0.03 mM for the wild-type carboxylase and 2.08 6 0.23 mM for
mutant L394R.
FIG. 6. Inhibition of FIXproGla carboxylation by ProFIX19.
The relative rate (Vi/Vo) of FIXproGla carboxylation at ProFIX19 con-
centrations between 0 and 10 mM is shown for the wild-type carboxylase
(filled squares) and mutant L394R (filled circles). Vo is
14CO2 incorpo-
ration in the absence of ProFIX19, and Vi is
14CO2 incorporation at a
given concentration of ProFIX19. The reactions were performed at 0.5
mM FIXproGla (2-fold Km) for the wild-type carboxylase and 4.0 mM
FIXproGla (2-fold Km) for mutant L394R. The Ki determined is 63 6 13
and 459 6 28 nM for the wild type and mutant L394R, respectively.
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394 to arginine results in a striking defect in the catalytic
efficiency of the carboxylase toward the small substrate
FLEEL.
In contrast to FLEEL, the more physiological substrate, FIX-
proGla, which has 12 Glu residues, has a slightly higher (;2-
fold) Vmax and a 9-fold higher Km for the mutant enzyme than
for the wild-type g-glutamyl carboxylase. Other carboxylase
mutations with higher Vmax and Km have been reported (39).
The increased Vmax for the mutant is consistent with our pre-
vious suggestions that product release is the rate-limiting step
for propeptide-containing substrates (the propeptide of the vi-
tamin K-dependent proteins is the primary binding site for the
carboxylase-substrate interaction (35, 40)) and that all car-
boxylations occur during a single binding event (41). Since the
assay measures only CO2 incorporation and not complete car-
boxylation of a 12-Glu substrate, any decrease in peptide affin-
ity can increase the Vmax, due to an increased off-rate, and may
also result in undercarboxylated products. For L394R,
FLEEL’s Vmax is slower because CO2 incorporation, rather
than off-rate, is the rate-limiting step.
L394R also has smaller but significant effects on the propep-
tide and vitamin K interactions. The propeptide concentration
required for half-maximal stimulation of FLEEL carboxylation
was 15-fold higher, while the Ki for the inhibition of CO2
incorporation into FIXproGla by FIX’s propeptide was 7-fold
higher for L394R than for the wild-type enzyme. L394R’s Km
for vitamin K was also 5-fold higher than that of the wild-type
enzyme. These results seem consistent with previous studies
suggesting that the propeptide, vitamin K, and glutamate bind-
ing site are functionally linked (33, 34, 42). Thus, while the
primary defect in L394R is glutamate substrate binding, link-
age of this site to the other substrate sites results in a complex,
multifaceted effect on enzyme activity.
There are several features of this mutation that make it
interesting. First, the mutated residue is one of 20 contiguous
amino acids that are identical in human (19), bovine (20), rat
(21), Drosophila (22), mouse, whale, toadfish, and chicken (23).
Second, the mutation is a drastic one, a hydrophobic residue to
a charged residue. This almost certainly means that the mu-
tation is a surface residue. If it were not, we would expect a
very unstable protein with little activity. However, mutant
L394R is stable and, under appropriate conditions, has sub-
stantial activity. Surface hydrophobic amino acids are often
found to be important for protein-protein or protein-substrate
interactions (43); therefore, it is likely that leucine 394 is a
surface residue that contributes to substrate binding. Thus,
although not previously implicated in glutamate binding (44),
we postulate that this region of the carboxylase is a function-
ally important part of the glutamate-binding site.
The most interesting question, then, is how to relate our
observations on the purified carboxylases to the symptoms of
the patients carrying the mutation L394R. The original reports
(16, 18) demonstrated that vitamin K administration partially
ameliorated the patients’ bleeding problems. Therefore, we
originally hypothesized that the defect in L394R is in the
vitamin K interaction. As described here, however, reduced
interactions with vitamin K are apparently not the principal
defect. As mentioned above, it has been shown that the propep-
tide of the vitamin K-dependent proteins provides the primary
binding site for the enzyme-substrate interaction (35, 40). We
have also shown that patients who synthesize carboxylation-
deficient factor IX, when the vitamin K concentration is re-
duced by warfarin therapy, have a factor IX propeptide with
reduced affinity for the g-glutamyl carboxylase (45). Further-
more, carboxylation appears to occur processively and, during a
single binding event, modifies all of the glutamic acids that will
be carboxylated (41). Thus, anything that reduces the affinity
of the substrate for the carboxylase will result in a shorter
residence time of the substrate on the carboxylase, resulting in
its more rapid release and leading, potentially, to partially
carboxylated, inactive products. Similarly, anything that de-
creases the rate of CO2 incorporation may result in the normal
residence time being insufficient for complete carboxylation
before the product is released. Thus, any mutation that reduces
the affinity of the substrate for g-glutamyl carboxylase or re-
duces the rate of CO2 incorporation has the potential to result
in undercarboxylated products.
To understand how the effects listed above might explain the
therapeutic efficacy of vitamin K, we examined the effect of
vitamin K on the rate of carboxylation at a low FIXproGla
concentration, near the Km of the FIXproGla substrate for the
wild-type enzyme. It is often assumed that for maximum con-
trol of rates, substrates are present in vivo at concentrations
near their Km. Results (Fig. 8) show that, in contrast to high
FIXproGla concentrations, L394R has a lower Vmax than wild-
FIG. 7. Carboxylation of FIXproGla at varying vitamin KH2
concentrations. Carboxylation of FIXproGla, measured by 14CO2 in-
corporation, at vitamin KH2 concentrations between 0 and 222 mM, is
shown for the wild-type carboxylase (filled squares) and mutant L394R
(filled circles). FIXproGla at concentrations of 1.2 (5-fold Km) and 10.0
mM (5-fold Km) were used for the wild-type carboxylase and mutant
L394R, respectively. The Km is 7.0 6 1.2 mM for the wild-type carbox-
ylase and 32.8 6 5.4 mM for mutant L394R.
FIG. 8. The influence of vitamin KH2 on the carboxylation of
FIXproGla at 0.25 mM. Carboxylation of 0.25 mM FIXproGla at vitamin
KH2 concentrations between 0 and 222 mM was measured by
14CO2
incorporation for both the wild-type carboxylase (filled squares) and
mutant L394R (filled circles).
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type carboxylase at lower concentrations of substrate, but the
activity is increased from a low level to approximately 33% of
wild type by increasing vitamin K. Based on our results, we
conclude that the effect of vitamin K is merely an increased
rate of carboxylation, driving the processive carboxylation of
the vitamin K-dependent protein toward completion. After all,
vitamin K is the only substrate whose in vivo concentration can
be clinically manipulated. It should also be noted that vitamin
K only partially corrects this deficiency, and, consistent with
results shown in Fig. 8, the coagulation activity of these indi-
viduals remains below the normal range after vitamin K treat-
ment. (18)
Thus, the defect can be explained by a reduced rate of car-
boxylation, which is a result of a defective glutamate binding
site and increased Km for vitamin K. This effect would be
exacerbated by the apparent decreased affinity of the carbox-
ylase for the propeptide, resulting in a reduced residence time
for the substrate on the carboxylase. The combination of these
two effects would result in partially carboxylated vitamin K-
dependent proteins.
In summary, we have presented a plausible scenario to ex-
plain the amelioration of the patients’ symptoms in response to
vitamin K therapy. Our data show that the L394R mutant
g-glutamyl carboxylase has an impaired glutamate-binding
site that is more pronounced in the absence of the propeptide.
We also note that, to a lesser degree, the mutation affects the
propeptide and KH2 binding properties of the enzyme. These
apparent defects in binding propeptide and KH2 probably arise
because of linkage between different binding sites on the
carboxylase.
Acknowledgments—We thank Dr. D. L. Straight and Dr. H. H.
Thijssen for critically reviewing the manuscript and Jonathan D’Amore
and Dr. Laura Gabiger for editorial assistance.
REFERENCES
1. Suttie, J. W. (1985) Annu. Rev. Biochem. 54, 459–477
2. Suttie, J. W. (1980) CRC Crit. Rev. Biochem. 8, 191–223
3. Price, P. A. (1988) Annu. Rev. Nutr. 8, 565–583
4. Manfioletti, G., Brancolini, C., Avanzi, G., and Schneider, C. (1993) Mol. Cell.
Biol. 13, 4976–4985
5. Nelsestuen, G. L. (1976) J. Biol. Chem. 251, 5648–5656
6. Esmon, C. T., Sadowski, J. A., and Suttie, J. W. (1975) J. Biol. Chem. 250,
4744–4748
7. Wallin, R., and Suttie, J. W. (1982) Arch. Biochem. Biophys. 214, 155–163
8. Morris, D. P., Soute, B. A., Vermeer, C., and Stafford, D. W. (1993) J. Biol.
Chem. 268, 8735–8742
9. Fasco, M. J., Hildebrandt, E. F., and Suttie, J. W. (1982) J. Biol. Chem. 257,
11210–11212
10. McMillan, C. W., and Roberts, H. R. (1966) N. Engl. J. Med. 274, 1313–1315
11. Chung, K. S., Bezeaud, A., Goldsmith, J. C., McMillan, C. W., Menache, D.,
and Roberts, H. R. (1979) Blood 53, 776–787
12. Johnson, C. A., Chung, K. S., McGrath, K. M., Bean, P. E., and Roberts, H. R.
(1980) Br. J. Haematol. 44, 461–469
13. Goldsmith, G. H., Jr., Pence, R. E., Ratnoff, O. D., Adelstein, D. J., and Furie,
B. (1982) J. Clin. Invest. 69, 1253–1260
14. Vicente, V., Maia, R., Alberca, I., Tamagnini, G. P., and Lopez Borrasca, A.
(1984) Thromb. Haemostasis 51, 343–346
15. Pauli, R. M., Lian, J. B., Mosher, D. F., and Suttie, J. W. (1987) Am. J. Hum.
Genet. 41, 566–583
16. Brenner, B., Tavori, S., Zivelin, A., Keller, C. B., Suttie, J. W., Tatarsky, I., and
Seligsohn, U. (1990) Br. J. Haematol. 75, 537–542
17. Pechlaner, C., Vogel, W., Erhart, R., Pumpel, E., and Kunz, F. (1992) Thromb.
Haemostasis 68, 617
18. Brenner, B., Sanchez-Vega, B., Wu, S. M., Lanir, N., Stafford, D. W., and
Solera, J. (1998) Blood 92, 4554–4559
19. Wu, S. M., Cheung, W. F., Frazier, D., and Stafford, D. W. (1991) Science 254,
1634–1636
20. Rehemtulla, A., Roth, D. A., Wasley, L. C., Kuliopulos, A., Walsh, C. T., Furie,
B., Furie, B. C., and Kaufman, R. J. (1993) Proc. Natl. Acad. Sci. U. S. A. 90,
4611–4615
21. Romero, E. E., Deo, R., Velazquez-Estades, L. J., and Roth, D. A. (1998)
Biochem. Biophys. Res. Commun. 248, 783–788
22. Li, T., Yang, C. T., Jin, D., and Stafford, D. W. (2000) J. Biol. Chem. 275,
18291–18296
23. Begley, G. S., Furie, B. C., Czerwiec, E., Taylor, K. L., Furie, G. L., Bronstein,
L., Stenflo, J., and Furie, B. (July 12, 2000) J. Biol. Chem. 10.1074/jbc.
M003944200
24. Wu, S. M., Soute, B. A., Vermeer, C., and Stafford, D. W. (1990) J. Biol. Chem.
265, 13124–13129
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